• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Can J Neurol Sci . Neurological Presentations in Patients with COVID-19 in Cytokine Storm

tetano

Editor, Senior Moderator
Can J Neurol Sci


. 2021 Oct 29;1-7.
doi: 10.1017/cjn.2021.247. Online ahead of print.
Neurological Presentations in Patients with COVID-19 in Cytokine Storm


Gorkem Tutal Gursoy[SUP] 1 [/SUP], Hatice Yuksel[SUP] 1 [/SUP], Inci Mulkem Simsek[SUP] 1 [/SUP], Saniye Oral[SUP] 1 [/SUP], Fadime Erdogan Kucukdagli[SUP] 1 [/SUP], Ayberk Karaman[SUP] 2 [/SUP], Esragul Akinci[SUP] 3 [/SUP], Aliye Bastug[SUP] 3 [/SUP], Hatice Rahmet Guner[SUP] 3 [/SUP], Hesna Bektas[SUP] 1 [/SUP]



Affiliations

Abstract

Background: Coronavirus disease 2019 (COVID-19) infection causes a wide variety of neurological disorders by affecting both central and peripheral nervous systems. The cytokine storm (CS) has been blamed for the development of severe neurological disorders in COVID-19. However, the relationship between COVID-19 CS and neurological manifestations has not been adequately studied. Thus, we aimed to investigate the neurological presentations in patients with COVID-19 CS.
Methods: The study population consisted of hospitalized moderate-to-severe COVID-19 patients. It was divided into two groups CS (36 patients, 29.3%) and non-CS (87 patients, 70.7%) based on significant clinical symptoms, elevated inflammatory marker levels, radiological findings, and interleukin-6 levels (IL-6).
Results: The three most common neurological symptoms in the CS group were altered level of consciousness, headache, and unsteadiness. Altered level of consciousness was higher in the CS group (69.4%) than the non-CS group (25.3%) (p:0.001). The frequency of headache was comparable in both groups (p:0.186). The number of patients requiring intensive care unit and intubation was higher in the CS group (p:0.005 and p:0.001). The mortality rate in the CS group (38.9%) was higher than the non-CS group (8.0%) (p:0.001). IL-6, CRP, ferritin, neutrophil-lymphocyte ratio, procalcitonin, and D-dimer levels were higher in the CS group (for all p:0.001) while lymphocyte count was lower (p:0.003).
Conclusion: The most common neurological presentation in patients with CS was altered level of consciousness. The presence of CS was an independent risk factor for high mortality.

Keywords: Altered level of consciousness; COVID-19; Cytokine storm; Interleukin-6; Neurological disorders.
 
Back
Top Bottom